GABRA6: A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: GABRA6

NCBI ID: G2559

GABRA6

Other Name(s): gamma-aminobutyric acid type A receptor subunit alpha6 | gamma-aminobutyric acid (GABA) A receptor, alpha 6 | Gamma-aminobutyric acid A receptor, alpha 6 | Gamma-aminobutyric acid type A receptor subunit alpha6 | gamma-aminobutyric acid type A receptor alpha6 subunit | GABA(A) receptor subunit alpha-6 | GABA(A) receptor, alpha 6 | GBRA6_HUMAN | Gamma-aminobutyric acid receptor subunit alpha-6 | GABA subunit A receptor alpha 6

GABRA6: A Potential Drug Target and Biomarker for Alzheimer's Disease

Introduction

Alzheimer's disease is a neurodegenerative disorder that is characterized by the progressive accumulation of neurofibrillary tangles and the loss of brain cells. It is the most common cause of dementia among older adults and is associated with significant morbidity and mortality. The underlying cause of Alzheimer's disease is not fully understood, but research has identified several potential drug targets and biomarkers that may be associated with the disease. One of these targets is GABRA6, a GABA-伪6 receptor subunit that is expressed in various tissues and plays a critical role in neural function. In this article, we will explore the potential role of GABRA6 as a drug target and biomarker for Alzheimer's disease.

GABA-伪6 Receptor: Structure and Function

GABA (纬-aminobutyric acid) is a neurotransmitter that plays a critical role in the regulation of neural activity and has been linked to a number of neurological and psychiatric disorders. The GABA-伪6 receptor is a GABA receptor that is primarily expressed in the brain and is involved in the regulation of neural circuits and behaviors. The GABA-伪6 receptor is composed of an extracellular domain, a transmembrane domain, and an intracellular domain that is involved in the formation of ion channels and intracellular signaling pathways.

GABRA6 is a type A GABA-伪6 receptor subunit that is expressed in various tissues, including the brain, heart, and pancreas. It is involved in the regulation of neural circuits and is thought to play a role in the development and progression of Alzheimer's disease . GABA6 has been shown to be involved in the formation of neurofibrillary tangles, which are thought to be a hallmark of Alzheimer's disease, and has been linked to the loss of brain cells in the disease.

Drug Targeting Strategies for GABRA6

GABRA6 has been identified as a potential drug target for Alzheimer's disease due to its involvement in the regulation of neural circuits and its role in the formation of neurofibrillary tangles. There are several strategies that have been proposed for targeting GABRA6, including:

1. antagonism of GABRA6: One approach to targeting GABRA6 is to antagonize its activity by using drugs that bind to the receptor. This can be done either by blocking the extracellular domain of the receptor or by blocking the intracellular domain. One such drug is baclofen , which is a muscle relaxant that has been shown to block GABRA6 in animal models of Alzheimer's disease.
2. Blockade of GABRA6 signaling pathways: Another approach to targeting GABRA6 is to block the signaling pathways that are activated by GABRA6. This can be done by using drugs that inhibit the activity of GABA-伪6 receptor antagonists or by using drugs that activate GABA- 伪6 receptor signaling pathways. One such drug is Regulatory Factor-1 (RGD2), which is a small molecule that can activate GABA-伪6 receptor signaling pathways and has been shown to protect against the neurotoxicity of neurofibrillary tangles in animal models of Alzheimer's disease.
3. modulation of GABRA6 expression: modulation of GABRA6 expression can be done by using drugs that interfere with the ability of GABA to bind to the receptor or by using drugs that alter the stability of GABA-伪6 receptor.

Biomarkers for GABRA6

GABRA6 is an attractive target for drug development in Alzheimer's disease due to its involvement in the regulation of neural circuits and its role in the

Protein Name: Gamma-aminobutyric Acid Type A Receptor Subunit Alpha6

Functions: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel

The "GABRA6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GABRA6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets